Equashield Overview
Equashield Medical provides advanced, automated solutions to protect healthcare workers and facilities from the risks associated with hazardous drug exposure and contamination. The company has developed two major patented products: Equashield CSTD and Equashield Pro. Equashield CSTD is an airtight closed-system drug-transfer device that protects against occupational exposure to hazardous drugs. Equashield Pro is an automatic compounding system specially designed to handle multiple tasks simultaneously while using advanced proprietary image-processing algorithms to monitor and control all stages of the process.
Cumulative Funding Raised Over Time ($)
—Aug 2024
Latest News
growth-positive
Biotech company Equashield sells 25% stake to Nordic Capital at $1.3 billion valuation | CTech
Israeli company Equashield has sold a 25% stake to private equity firm Nordic Capital for $300 million, giving it a valuation of $1.3 billion and making it a unicorn. Equashield, founded in 2008, provides manual and automated solutions for the compounding and administration of hazardous drugs to hospitals worldwide. The deal marks Nordic Capitals first investment in an Israeli company. Prior to the deal, Equashield distributed approximately $28 million in dividends to its shareholders. The companys largest shareholder is CEO and co-founder Eric Shem-Tov.
Investment
growth-positive
Equashield's State-of-the-Art Manufacturing Complex Fulfilling Customer Orders at Record Pace
Equashield, a leading provider of closed system transfer devices (CSTDs) for hazardous drugs, announced that its automated manufacturing facility is helping the company fulfill large quantity customer orders on-time, neutralizing global supply chain challenges. The facility, equipped with machine learning and artificial intelligence, allows for fully automated production and quick supply fulfillment. Equashields CSTD portfolio provides safety and ease of use for healthcare workers handling hazardous drugs. The companys growth and investment in manufacturing technology have paid off, enabling them to meet market demands and ensure quality assurance.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 1 |
| Investors | 0 |
Team Members
8
Employees: 51-200
Web & Social Links
| Website | www.equashield.com/ |
| Careers | Careers page |
Locations
Dolev St 2, תפן, 2495900, Israel
2 Harbor Park Dr, Port Washington, NY 11050, USA
Photos & Videos
1 item(s)
Equashield Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersMedical Devices IndustryMedical EquipmentCore Technology
Machinery & RoboticsProcessing MachineryIndustrial RobotsTags (3)
automationdrugs-managementmedical-devicesSolutions
{"title":"Healthcare (Pharmacy & Oncology Safety)","description":"A Closed System Transfer Device (CSTD) designed to prevent healthcare worker exposure to hazardous drugs, particularly in oncology and chemotherapy, by ensuring a closed and contained drug transfer process.","items":[{"name":"Revenue Growth","value":1,"titleTooltip":"Revenue Growth & Profitability","meterTooltip":{"title":"Negligible / Incidental","content":"No discernible or only trivial positive effect; status-quo unchanged."}},{"name":"Operational Efficiency","value":3,"titleTooltip":"Operational Excellence & Efficiency","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Customer Acquisition","value":2,"titleTooltip":"Customer Acquisition, Satisfaction & Loyalty","meterTooltip":{"title":"Marginal / Localized","content":"Small, isolated improvement; measurable but not substantial."}},{"name":"Risk Mitigation","value":4,"titleTooltip":"Risk Mitigation & Business Resilience","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Talent Development","value":4,"titleTooltip":"Talent Development & Employee Empowerment","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Agility & Innovation","value":3,"titleTooltip":"Strategic Agility & Innovation","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}}]}
{"title":"Healthcare","description":"EQUASHIELD® Pro is a closed system transfer device (CSTD) designed to prevent healthcare worker exposure to hazardous drugs, ensuring safety, compliance with regulations like USP <800>, and improving efficiency in drug preparation and administration.","items":[{"name":"Revenue Growth","value":3,"titleTooltip":"Revenue Growth & Profitability","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Operational Efficiency","value":4,"titleTooltip":"Operational Excellence & Efficiency","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Customer Acquisition","value":3,"titleTooltip":"Customer Acquisition, Satisfaction & Loyalty","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Risk Mitigation","value":5,"titleTooltip":"Risk Mitigation & Business Resilience","meterTooltip":{"title":"Disruptive / Paradigm-Shifting","content":"Revolutionary, industry-leading change that sets new benchmarks and norms."}},{"name":"Talent Development","value":4,"titleTooltip":"Talent Development & Employee Empowerment","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Agility & Innovation","value":3,"titleTooltip":"Strategic Agility & Innovation","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}}]}
Use Cases
The EQUASHIELD® CSTDEQUASHIELD® ProGeographic Markets
GlobalEquashield Financials
Undisclosed
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
1
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
—Aug 2024
Private Equity Funding
Secondary Round
Aug 2024
Undisclosed
Public Offering / Exit
MNAEvent
Oct 2022
$300M
Equashield Lifecycle
Cumulative Funding Raised Over Time
—Aug 2024
All Events
Secondary Round
Aug 2024
Undisclosed
MNAEvent
Oct 2022
$300M
Equashield News
2 articles
growth-positive
Biotech company Equashield sells 25% stake to Nordic Capital at $1.3 billion valuation | CTech
Israeli company Equashield has sold a 25% stake to private equity firm Nordic Capital for $300 million, giving it a valuation of $1.3 billion and making it a unicorn. Equashield, founded in 2008, provides manual and automated solutions for the compounding and administration of hazardous drugs to hospitals worldwide. The deal marks Nordic Capitals first investment in an Israeli company. Prior to the deal, Equashield distributed approximately $28 million in dividends to its shareholders. The companys largest shareholder is CEO and co-founder Eric Shem-Tov.
Investment
growth-positive
Equashield's State-of-the-Art Manufacturing Complex Fulfilling Customer Orders at Record Pace
Equashield, a leading provider of closed system transfer devices (CSTDs) for hazardous drugs, announced that its automated manufacturing facility is helping the company fulfill large quantity customer orders on-time, neutralizing global supply chain challenges. The facility, equipped with machine learning and artificial intelligence, allows for fully automated production and quick supply fulfillment. Equashields CSTD portfolio provides safety and ease of use for healthcare workers handling hazardous drugs. The companys growth and investment in manufacturing technology have paid off, enabling them to meet market demands and ensure quality assurance.
Customers
Equashield Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 126 |
| Team members | 8 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Equashield Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514262021 |
| Crunchbase | equashield-medical |
| Phone | +97299716111 |
| Creator | Matan Eblagon |
| Creator email | matane@sncentral.org |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2022-12-22T00:00:00.000Z |
| Created | 2022-12-11T00:00:00.000Z |
| Status detail | Acquired by Nordic Capital on Oct, 2022 |